|
|
Sale of exploration interest |
|
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to announce that it has reached agreement with Regis Resources Limited (“Regis”) to dispose of its minority interest in the North Laverton Joint Venture (the “Joint Venture”) |
|
|
Genetic Technologies Clarifies Misconceptions on BRCA testing |
|
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) today clarified reported misconceptions arising from its plans to enforce its exclusive intellectual property rights in relation to BRCA1 and BCRA2 hereditary breast and ovarian cancer testing. |
|
GTG acquires Frozen Puppies |
|
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to announce it has acquired Frozen Puppies Dot Com Pty. Ltd. (“FPDC”), Australia’s foremost provider of canine reproductive services. |
|
|
Genetic Technologies to enforce rights to BRCA patents |
|
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) has made a commercial decision to enforce the rights granted to it under an exclusive license from Myriad Genetics Inc. to use Myriad’s patents to perform diagnostic testing of the BRCA1 and BRCA2 genes in Australia and New Zealand. |
|
Granting and cancellation of options |
Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) reports the granting of 1,000,000 unlisted options over ordinary shares in the Company, details of which are included on the attached Appendix 3B
|
|
|
|
|
<< Start < Prev 21 22 23 24 25 26 27 28 29 30 Next > End >>
|
|
Page 27 of 30 |
